K2M Group Holdings Inc. (NASDAQ:KTWO)’s share price traded up 4.8% during trading on Wednesday . The company traded as high as $16.74 and last traded at $16.54, with a volume of 304,024 shares trading hands. The stock had previously closed at $15.78.

A number of equities analysts have recently commented on the stock. Piper Jaffray Cos. reissued a “buy” rating on shares of K2M Group Holdings in a research report on Monday, April 25th. JMP Securities initiated coverage on shares of K2M Group Holdings in a research report on Friday, April 8th. They set an “outperform” rating and a $25.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of K2M Group Holdings in a research report on Tuesday, May 3rd. Northland Securities lowered shares of K2M Group Holdings from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 3rd. Finally, Zacks Investment Research lowered shares of K2M Group Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. K2M Group Holdings has an average rating of “Buy” and an average price target of $23.25.

The company’s market cap is $691.97 million. The stock has a 50-day moving average price of $14.27 and a 200 day moving average price of $14.34.

K2M Group Holdings (NASDAQ:KTWO) last posted its earnings results on Monday, May 2nd. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.02. The company earned $56.20 million during the quarter, compared to analyst estimates of $56 million. During the same period last year, the firm posted ($0.37) earnings per share. The business’s quarterly revenue was up 11.7% compared to the same quarter last year. On average, equities research analysts expect that K2M Group Holdings Inc. will post ($1.10) EPS for the current fiscal year.

In other K2M Group Holdings news, CFO Gregory S. Cole sold 6,465 shares of the company’s stock in a transaction that occurred on Saturday, May 21st. The stock was sold at an average price of $11.32, for a total transaction of $73,183.80. Following the completion of the transaction, the chief financial officer now owns 33,233 shares of the company’s stock, valued at approximately $376,197.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Carlos A. Ferrer purchased 20,000 shares of K2M Group Holdings stock in a transaction on Thursday, May 5th. The shares were purchased at an average cost of $11.32 per share, with a total value of $226,400.00. Following the transaction, the director now owns 59,382 shares in the company, valued at $672,204.24. The disclosure for this purchase can be found here.

A number of institutional investors have recently added to or reduced their stakes in KTWO. OppenheimerFunds Inc. increased its position in K2M Group Holdings by 13.1% in the fourth quarter. OppenheimerFunds Inc. now owns 908,054 shares of the medical device company’s stock worth $17,925,000 after buying an additional 105,014 shares during the period. Principal Financial Group Inc. increased its position in K2M Group Holdings by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 398,277 shares of the medical device company’s stock worth $7,862,000 after buying an additional 5,127 shares during the period. Nationwide Fund Advisors increased its position in K2M Group Holdings by 3.8% in the fourth quarter. Nationwide Fund Advisors now owns 98,318 shares of the medical device company’s stock worth $1,941,000 after buying an additional 3,597 shares during the period. Paradigm Capital Management Inc. NY increased its position in K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock worth $3,350,000 after buying an additional 146,300 shares during the period. Finally, Columbus Circle Investors increased its position in K2M Group Holdings by 20.4% in the fourth quarter. Columbus Circle Investors now owns 510,062 shares of the medical device company’s stock worth $10,069,000 after buying an additional 86,497 shares during the period.

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.